Biomarkers and biomeasures: Key enablers for pharmacokinetic- pharmacodynamic modeling in drug discovery and development

Bioanalysis

Volumn 4, Issue 10, 2012, Pages 1143-1145

  Agoram, Balaji M ^a   Van Der Graaf, Piet H ^b  

^a MEDIMMUNE   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

systems pharmacology

Indexed keywords

BIOLOGICAL MARKER; CALCIMIMETIC AGENT; GLUCAGON LIKE PEPTIDE 1; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; INSULIN; INSULIN RECEPTOR; PARATHYROID HORMONE;

ACCURACY; ADIPOCYTE; ALLERGIC ASTHMA; ANALYTIC METHOD; CHEMICAL MODEL; CONFOCAL MICROSCOPY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESEARCH; DRUG SAFETY; ENDOCYTOSIS; FLOW CYTOMETRY; HUMAN; IMMUNOASSAY; PHARMACOKINETIC PHARMACODYNAMIC MODELING; RECEPTOR DENSITY; RECEPTOR OCCUPANCY; REVIEW; SIMULATION; SYSTEMS BIOLOGY;

BIOLOGICAL MARKERS; COMPUTER SIMULATION; DRUG DISCOVERY; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS;

EID: 84861864253     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.12.88     Document Type: Review

References (11)

1. Gabrielsson J, Fjellstrom O, Ulander J et al. Pharmacodynamic- pharmacokinetic integration as a guide to medicinal chemistry. Curr. Top. Med. Chem. 11(4), 404-418 (2011
2. Agoram BM, Demin O. Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development. Drug Discov. Today 16(23-24), 1031-1036 (2011
3. van der Graaf PH, Benson N. Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PK/PD) in drug discovery and development. Pharm. Res. 28 (7), 1460-1464 (2011
4. Rowland M, Towzer R. Clinical Pharmacokinetics (Fourth Edition).Lippincott, Williams & Wilkins, MD, USA, 3-17 (2007
5. Danhof M, De Jongh J, De Lange EC, Della Pasqua O, Ploeger BA, Voskuyl RA. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu. Rev. Pharmacol. Toxicol. 47, 357-400 (2007
6. Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br. J. Clin. Pharmacol. 68(1), 61-76 (2009
7. Ng CM, Stefanich E, Anand BS et al. Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm. Res. 23(1), 95-103 (2006
8. Wang B, Lau YY, Liang M et al. Mechanistic modeling of antigen sink effect for mavrilimumab following intravenous administration in patients with rheumatoid arthritis. J. Clin. Pharmacol. doi:10.1177/0091270011412964 (2011) (Epub ahead of print
9. Nyman E, Brannmark C, Palmer R et al. Hierarchical whole-body modeling approach elucidates the link between in vitro insulin signaling and in vivo glucose homeostasis. J. Biol. Chem. 286(29), 26028-26041 (2011
10. Roskos LK, Schneider A, Vainshtein I et al. PK-PD modeling of protein drugs: implications in assay development. Bioanalysis 3(6), 659-675 (2011
11. Van der Graaf PH, Danhof M. Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic- pharmacodynamic modelling. Int. J. Clin. Pharmacol. Ther. 35(10), 442-446 (1997